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Tuesday, February 5, 2013 443aevidence for protein conformational changes upon ATP or caffeine binding.
We observed a similar binding affinity of the expressed RyR2 central domain
for both compounds, with an EC50 ~100mM. The presence of the individual
mutations made no apparent difference to the EC50. However, there was an in-
creased initial fluorescence value observed for each of the mutant constructs
compared to WT. Analysis of the central domain sequence revealed homology
with conserved motifs typical of P-loop kinases. Interestingly, many of the
CPVT mutations present in this region are coincident with sites corresponding
to the Walker A, Walker B and LID motifs in ATP binding proteins.
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The ryanodine receptor (RyR) is an intracellular ion channel with an important
role in depolarization-induced Ca2þ release in excitable cells. For the skeletal
muscle isoform RyR1, the open and closed conformations were determined at
10 A˚ resolution by cryoEM, and their structural analysis suggest that RyR1,
with four inner helices forming a helical bundle, has a similar gating mechanism
to that of Kþ channels. Upon gating, RyR1’s large cytoplasmic domain also un-
dergoes conformational changes, underlying a long-range communication path-
way between the ion gate and effectors bound more than 130 A˚ away. One of
such effectors is the FK506-binding protein of 12 kDa (FKBP12), which we lo-
calized at the interface of the ‘‘handle’’ and the ‘‘clamp’’ domains of RyR1. At
the functional level, and under activating [Ca2þ] concentrations, single channel
experiments with purifiedRyR1 show that FKBP12 increasedRyR1’s Po and re-
distributed its subconductance states towards higher conductance levels. At the
structural level, we found that under sub-activating [Ca2þ] concentrations and in
the absence of FKBP12, RyR1’s cytoplasmic domain appears to be a structural
intermediate of the well-defined open- and closed-state RyR1-FKBP12 confor-
mations, whereas the inner helices remain in the closed conformation. Overall,
our studies suggest that while [Ca2þ] exerts a dominant effect in RyR1’s gating,
FKBP12 changes the energy landscape of RyR1’s structural transitions.
2270-Pos Board B289
Stabilization of the Skeletal Muscle Ryanodine Receptor Ion Channel-
FKBP12 Complex by the 1,4-Benzothiazepine Derivative S107
Yingwu Mei1, Le Xu1, Henning H. Kramer2, Ginger H. Tomberlin2,
Claire Townsend2, Gerhard Meissner1.
1The University of North Carolina, Chapel Hill, NC, USA,
2GlaxoSmithKline, Research Triangle Park, NC, USA.
Activation of the skeletal muscle ryanodine receptor (RyR1) complex results in
the rapid release of Ca2þ from the sarcoplasmic reticulum and muscle contrac-
tion. Dissociation of the small FK506-binding protein 12 subunit (FKBP12) in-
creases RyR1 activity and leads to the impairment of muscle function. The 1,4-
benzothiazepine derivative JTV519, and more specific derivative S107
(2,3,4,5,-tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine), are thought to
improve skeletal muscle function by stabilizing the RyR1-FKBP12 complex.
Here, we report that SR vesicles enriched in RyR1 bound a large number of
S107 molecules with micromolar affinity. The effects of S107 and FKBP12
on RyR1 were examined under conditions that altered the redox state of
RyR1. In SR vesicles, S107 increased FKBP12 binding to RyR1 in presence
of reduced glutathione and the NO-donor NOC12. S107 was without effect
in the presence of oxidized glutathione. Addition of 0.15 mM FKBP12 to SR
vesicles prevented FKBP12 dissociation, whereas in the presence of oxidized
glutathione and NOC12 FKBP12 dissociation was observed in skeletal muscle
homogenates that contained 0.43 mM myoplasmic FKBP12, and this dissocia-
tion was attenuated by S107. In single channel measurements, pretreatment of
FKBP12-depleted RyR1s with S107 in the absence and presence of NOC12
augmented the FKBP12-mediated decrease in channel activity. The data sug-
gest that S107 can reverse the harmful effects of redox active species on SR
Ca2þ release in skeletal muscle.
2271-Pos Board B290
Investigating the Relationship between FKBP Structure and the Ability to
Activate RyR Channels
Elena Galfre`1, Elisa Venturi1, Samantha J. Pitt2, Stuart Bellamy1,
Richard B. Sessions1, Rebecca Sitsapesan1.
1University of Bristol, Bristol, United Kingdom, 2University of St Andrews,
St Andrews, United Kingdom.
We have recently demonstrated, both at the single-channel level and in iso-
lated cardiac cells (Galfre et al., (2011) PLoS ONE, 7, Issue 2, e31956), that
the cardiac RyR (RyR2) is activated by FKBP12 and that this effect is reg-
ulated by the antagonistic action of FKBP12.6. We now investigate whether
FKBPs can also activate skeletal RyR (RyR1) and examined the relationshipbetween FKBP structure and the ability to activate RyR1 and RyR2. We
generated a mutant FKBP12 (FKBP12E31Q/D32N/W59F) where the amino acids
Glu31, Asp32 and Trp59 were mutated to the respective residues found in
FKBP12.6 (Gln, Asn and Phe). The effects of the wild type and mutant
FKBP12E31Q/D32N/W59F proteins on the single-channel gating of RyR1 and
RyR2 were then compared. Our results show that FKBP12.6 promotes acti-
vation of RyR1 whereas FKBP12 promotes activation of RyR2. The FKBP12
mutant, FKBP12E31Q/D32N/W59F did not alter RyR2 Po (n=5) but caused sig-
nificant activation of RyR1; for example Po was 0.02150.008 before and
0.11050.026 after addition of cytosolic 1 mM FKBP12E31Q/D32N/W59F
(SEM; n=7; **p<0.01)). The FKBP12 mutant, therefore, no longer behaves
like FKBP12 but instead mimics the actions of FKBP12.6 on both RyR iso-
forms. In conclusion, we demonstrate that FKBP12 and FKBP12.6 specifi-
cally activate RyR2 and RyR1, respectively. Our results also suggest that
the ability of FKBP12 and FKBP12.6 to activate RyR channels is contained
within just three amino acid residues of FKBP12 (Glu31, Asp32 and Trp59)
and the corresponding residues in FKBP12.6 (Gln31, Asn32 and Phe59). These
results shed new light on the interactions of FKBPs with RyR channels and
will be important for understanding the dual role of FKBP12 and FKBP12.6
as regulators of sarcoplasmic reticulum Ca2þ-release in cardiac and skeletal
muscle.
Supported by the BHF
2272-Pos Board B291
FRET-based Mapping of Regions involved in FKBP12.6 Binding to the
Type 1 Ryanodine Receptor
Tanya Girgenrath1, Bengt Svensson2, Florentin Nitu2, Razvan L. Cornea2,
James D. Fessenden1.
1Brigham and Women’s Hospital, Boston, MA, USA, 2University of
Minnesota, Minneapolis, MN, USA.
The type 1 ryanodine receptor (RyR1) is an intracellular calcium channel that
plays an integral role in skeletal muscle excitation-contraction coupling. The
functional properties of this protein are regulated by numerous associated pro-
teins, including FKBP12, a skeletal muscle protein that stabilizes full RyR1
channel gating. While the binding site of FKBP12 was originally identified at
position 2458 of RyR1, subsequent reports have localized additional binding
determinants within the N-terminal domain of RyR1. In this study, we used
fluorescence resonance energy transfer (FRET) to determine the orientation
and proximity of FKBP relative to sites either within the N-terminal domain
or near amino acid position 2458. We utilized the cardiac muscle isoform
FKBP12.6 (which binds to RyR1 at the same site as FKBP12 but with higher
affinity and stability) labeled with the FRET donor Alexa Fluor 488 at either
position 14, 44, 49, or 85. Specific binding of each labeled FKBP to RyR was
confirmed in permeabilized HEK-293T cells expressing wtRyR1. Weak energy
transfer was observed from FKBP12.6 to the FRET acceptor Cy3NTA, which
was targeted to poly-histidine ‘‘tags’’ placed in the N-terminal domain. This re-
sult suggested that the acceptors were not proximal (~90A˚ away) to FKBP12.6
bound to RyR1. Next, we measured FRET from FKBP12.6 to Cy3NTA targeted
to positions 2157, 2341, 2502 and 2777 of RyR1. FKBP12.6 binding to con-
structs containing His-tags at positions 2157 and 2502 was significantly reduced
relative to binding to wtRyR1. In contrast, we detected strong and weak FRET
efficiencies from FKBP12.6 to positions 2341 and 2777, respectively. These
data suggest that FKBP12.6 binds near amino acid position 2341 but far from
the N-terminal domain of RyR1. Supported by NIH grant R01AR059124 (to
JDF and TG) and R01HL092097 (to RLC).
2273-Pos Board B292
Physiological Role(S) of RyR1 in Smooth Muscle Cells
Ruben Lopez1, Mirko Vukcevic1, Francesco Zorzato2,1, Susan Treves1,2.
1Kantonsspital Basel, Basel, Switzerland, 2University of Ferrara, Department
of Life sciences, Ferrara, Italy.
Type 1 ryanodine receptor (RyR1) is a key protein involved in the regulation of
the intracellular Ca2þ concentration in skeletal muscle cells, playing a crucial
role in muscle contraction by releasing Ca2þ from the sarcoplasmic reticulum
after plasma membrane depolarization. Dysregulation of calcium signals due to
defects in RyR1 have been associated with a wide range of primary neuromus-
cular disorders, including Malignant Hyperthermia Susceptibility and a number
of congenital myopathies including Core Myopathies, some forms of Centronu-
clear myopathy and congenital fiber type disproportion. Though RyR1 is pref-
erentially expressed in skeletal muscles recent data has shown that it is also
expressed in some areas of the central nervous system, in some cells of the im-
mune system (B-lymphocytes and dendritic cells) and in smooth muscle cells.
Thus mutations in RYR1 (the gene encoding RyR1) may lead to alterations of
Ca2þ homeostasis not only in skeletal muscle, but also in other tissues express-
ing this intracellular calcium release channel.
